ClinicalTrials.gg
RecruitingNCT04912596Updated Feb 17, 2025

Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma

An interventional study of Albuterol Sulfate inhalation aerosol 108 mcg per actuation and Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation in Mild Asthma, sponsored by Intech Biopharm Ltd.. Recruiting at 12 sites in 2 countries. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Intech Biopharm Ltd. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies testing albuterol in Asthma — 8 open to participants now, 9 under way, 1 of them phase 3. Albuterol · Asthma.

Planned enrollment
17th of 72
148 · median 63
Started
2022
with 1 other
No phase
17 of 72
3 open now
Registered
58th of 72
by date

Among the 72 studies testing albuterol in Asthma, this one is the 17th largest by planned enrollment, is one of 2 that started in 2022, is one of 17 with no phase, and was the 58th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

8 of the 72 studies testing albuterol in Asthma are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies testing albuterol in Asthma, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the pharmacodynamic (PD) bioequivalence (BE) of albuterol inhalers, test formulation: Albuterol Sulfate HFA inhalation aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation and reference formulation: ProAir HFA (albuterol sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation manufactured by two different manufacturers using methacholine bronchoprovocation challenge test in patients with stable mild asthma.

Read the detailed description

This study will be conducted using the single-dose, randomized, double-blind, double-dummy, four-sequence, four-treatment, and multiple-center study design to evaluate the PD bioequivalence between the test albuterol sulfate (T) inhalation aerosol 108 mcg per actuation (eq. to albuterol base 90 mcg/puff) and the reference albuterol sulfate (R) (ProAir HFA or FDA authorized generic: Albuterol Sulfate HFA [Teva Pharmaceutical USA, Inc.]) inhalation aerosol 108 mcg per actuation (equal to albuterol base 90 mcg/puff). The two products will be studied using a crossover design in patients with stable mild asthma by administering a minimum of 3 doses of reference product (0, 90, 180 mcg albuterol) and 2 doses of test product (0, 90 mcg albuterol). The bronchodilation potency of albuterol sulfate are measured by the inhibition effects of methacholine challenge on the bronchodilation, as indicated by increase in the provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20).

03

Conditions studied

  • Mild Asthma

Browse trials for

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, non-pregnant and non-lactating female subjects (20-65 years of age, inclusive).
  2. A clinical diagnosis of mild asthma with historical documentation of the asthma diagnosis according to either: (1) the National Asthma Education and Prevention Program (NAEPP) guidelines (2007) or (2) the Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention (2020).
  3. Stable mild asthma receiving the following required inhaled medications for at least 1 month prior to screening: Low doses of ICS alone, or in combination with SABA, used regularly with a stable regimen.
  4. (FEV1) ≥ 80% of the local predicted normal value after withholding SABA ≥ 8 hours.
  5. Airway responsiveness to methacholine demonstrated by a pre-albuterol-dose (baseline) PC20 ≤ 8 mg/mL.
  6. Nonsmoker for at least 6 months prior to the study and a maximum smoking history of 5 pack-years (the equivalent of one pack per day for 5 years).
  7. Provision of written .
  8. Other than asthma, in general good health.
  9. (BMI) between 17 and 35 kg/m2 (inclusive).
  10. Able to correctly use MDI inhalers.
  11. Able to perform valid and reproducible pulmonary function tests including no evidence of spirometry effort-induced bronchoconstriction.
  12. If the subject or subject's partner is of , a medically acceptable form of will be used for the duration of the study. Medically acceptable contraceptives include: (1) surgical sterilization, (2) Health Authority approved female hormonal contraceptives, (3) an intrauterine device (IUD), (4) condoms with spermicide, or (5) diaphragm with spermicide.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of conditions altering airway reactivity to methacholine, including upper or lower respiratory tract infections (e.g., pneumonia, viral bronchitis, allergic rhinitis, sinobronchitis, etc.) within 6 weeks before Screening.
  2. Evidence of a baseline \< 60% of the local predicted normal value or FEV1 \< 1.5 L.
  3. History of seasonal asthma exacerbations, in which case the subject should be studied outside of the relevant allergen season.
  4. History of cystic fibrosis, bronchiectasis, , or other respiratory diseases including COPD, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma, pulmonary fibrosis, pulmonary hypertension that, in the opinion of the Investigator, would compromise subject safety or interfere with the evaluations.
  5. History of cardiovascular, hematological, renal, neurologic, hepatic, psychiatric, endocrine dysfunction, including with evidence of ischemic heart diseases and significant arrhythmias.
  6. Treatment in an emergency room or hospitalization for acute asthmatic symptoms within 3 months prior to screening.
  7. Known intolerance or to any component of the albuterol MDI, beta2 receptor-agonist drug, HFA, any related compounds or methacholine.
  8. Need for daily oral within 3 months prior to screening.
  9. Cardiac arrhythmia or 12-lead electrocardiogram (ECG) abnormalities, that in the opinion of the Investigator would compromise subject safety or interfere with the evaluations, or a > 440 ms for males and > 460 ms for females using Fredericia formula.
  10. Subjects receiving beta blocker via any route or who may require beta blockers during the study.
  11. History of narrow angle glaucoma, convulsive disorders, hyperthyroidism, uncontrolled diabetes, paradoxical bronchospasm.
  12. History of .
  13. History of alcohol or drug abuse.
  14. Eye, brain, thoracic, and abdominal surgeries within 3 months prior to screening.
  15. Use of cromyolyn, leukotriene receptor antagonists (LTRA), nedocromil, zileuton, theophylline, or long-acting beta-agonists (LABA) within 1 month prior to screening.
  16. History of receiving muscarinic beta2-agonists (MABAs), short-acting muscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), anti-IgE, anti-IL5/5R, anti-IL4R, high dose ICS, or systemic corticosteroid for treatment of asthma within 6 months prior to screening.
  17. Known (HIV)-positive status.
  18. Participated in any interventional clinical trials within 1 month prior to screening.
  19. Pregnancy or breast feeding.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
148 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group

    Two different Reference Placebo inhalers and two different Test Placebo inhalers

    Other: Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo · Other: Albuterol Sulfate inhalation Placebo · Other: Methacholine

  • Active comparator
    Reference 1 group

    One Reference inhaler, one Reference Placebo inhaler, and two different Test Placebo inhalers

    Drug: Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation · Other: Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo · Other: Albuterol Sulfate inhalation Placebo · Other: Methacholine

  • Active comparator
    Reference 2 group

    Two different Reference inhalers and two different Test Placebo inhalers

    Drug: Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation · Other: Albuterol Sulfate inhalation Placebo · Other: Methacholine

  • Experimental
    Test group

    One Test inhaler, one Test Placebo inhaler, and two different Reference Placebo inhalers

    Drug: Albuterol Sulfate inhalation aerosol 108 mcg per actuation · Other: Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo · Other: Albuterol Sulfate inhalation Placebo · Other: Methacholine

Interventions

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    equal to albuterol 90 mcg/puff, MDI

    Also known as: Albuterol Sulfate

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    equal to albuterol 90 mcg/puff, MDI

    Also known as: Albuterol Sulfate

  • OtherProair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo

    MDI

  • OtherAlbuterol Sulfate inhalation Placebo

    MDI

  • OtherMethacholine

    Methacholine 100 mg/vial

06

What researchers measure

Primary outcomes

  1. Post-dose PC20 Concentration

    Post-dose PC20, which are the provocative concentrations, respectively, of the methacholine challenge agent required to reduce the forced expiratory volume in one second (FEV1) by 20% following administration of differing concentrations of albuterol (or placebo) by inhalation.

    Time frame: 15 minutes post-dose

07

Study locations

4 of 12 sites recruiting
  • Dr. Jivraj Mehta Smarak Health Foundation
    Ahmedabad, 38007, India
    Not yet recruiting
    • Vaishal Sheth · Contact
  • KLEs Dr Prabhakar Kore Hospital & MRC
    Belagave, 590010, India
    Not yet recruiting
    • Jyothi Hattiholi · Contact
  • NRS Medical College and Hospital
    Kolkata, 700014, India
    Not yet recruiting
    • Jaydip Deb · Contact
  • Medical College and Hospital
    Kolkata, 700073, India
    Not yet recruiting
    • Kaushik Saha · Contact
  • Aakash Healthcare Super Specialty Hospital
    New Delhi, 110075, India
    Not yet recruiting
    • Akshay Budhraja · Contact
  • Pimpri Chinchwad Municipal Corporation Post Graduate Institute Yashwantrao Chavan Memorial Hospital
    Pune, 411018, India
    Not yet recruiting
    • Pravin Soni · Contact
  • Kothrud Hospital
    Pune, 411038, India
    Not yet recruiting
    • Himanshu Pophale · Contact
  • Ashirwad Hospital and Research Centre
    Ulhasnagar, 421004, India
    Not yet recruiting
    • Shrikant Vishnu Deshpande · Contact
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
    Recruiting
    • Chau-Chyun Sheu, MD · Contact
  • Tamshui Mackay Memorial Hospital
    New Taipei City, 251, Taiwan
    Recruiting
    • Hsin-Pei Chung, MD · Contact
  • Taipei Medical University Hospital
    Taipei City, 110, Taiwan
    Recruiting
    • Pai-Chien Chou, MD, PhD · Contact
  • Shin Kong Wu Ho-Su Memorial Hospital
    Taipei City, 111, Taiwan
    Recruiting
    • Shih-Sen Lin, MD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2025, 29 months.

Of 50 industry-sponsored interventional studies with no phase under Asthma, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's 29 months is above that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 3, 2021
StartActual
Aug 15, 2022
Primary completionActual
Jan 31, 2025
CompletionEst.
Jun 2025
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04912596
Lead sponsor
Intech Biopharm Ltd.
Responsible party
Sponsor
First posted
Jun 3, 2021
Start date
Aug 15, 2022
Primary completion
Jan 31, 2025
Completion
Jun 2025 (estimated)
Last update
Feb 17, 2025

Study contacts

Jasmine Kuo
Contact
jasmine.i199@intechbiopharm.com
+886-2-7721-8877 ext. 688
Pai-Chien Chou, MD, PhD
principal investigator · Taipei Medical University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albuterol

Start the discussion